OA11011A - Quinoline-4-carboxamide derivatives their preparation and their use as neurokin 3 (nk-3)-and neurokin 2 (nk-2)receptor antagonists - Google Patents

Quinoline-4-carboxamide derivatives their preparation and their use as neurokin 3 (nk-3)-and neurokin 2 (nk-2)receptor antagonists Download PDF

Info

Publication number: OA11011A
Authority: OA; OAPI
Prior art keywords: group; alkyl; compound; formula; mmol
Prior art date: 1995-11-24

Application number

OA9800062A

Other languages

English (en)

Inventor

Giuseppe Amaldo Maria

Mario Grugni

Luca Francesco Raveglia

Carlo Farina

Original Assignee

Smithkline Beecham Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-11-24

Filing date

1998-05-22

Publication date

2003-03-06

1995-11-24 Priority claimed from ITMI952462 external-priority patent/IT1276171B1/it

1996-08-02 Priority claimed from IT96MI001688 external-priority patent/IT1307330B1/it

1998-05-22 Application filed by Smithkline Beecham Spa filed Critical Smithkline Beecham Spa

2003-03-06 Publication of OA11011A publication Critical patent/OA11011A/en

Links

LEWDKQKVAFOMPI-UHFFFAOYSA-N quinoline-4-carboxamide Chemical class C1=CC=C2C(C(=O)N)=CC=NC2=C1 LEWDKQKVAFOMPI-UHFFFAOYSA-N 0.000 title description 4
239000002464 receptor antagonist Substances 0.000 title description 4
229940044551 receptor antagonist Drugs 0.000 title description 4
238000002360 preparation method Methods 0.000 title description 2
150000001875 compounds Chemical class 0.000 claims abstract description 232
125000000217 alkyl group Chemical group 0.000 claims abstract description 43
-1 cyano, carboxy Chemical group 0.000 claims abstract description 41
125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 26
125000003118 aryl group Chemical group 0.000 claims abstract description 25
239000001257 hydrogen Substances 0.000 claims abstract description 23
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 23
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 21
125000000623 heterocyclic group Chemical group 0.000 claims abstract description 19
125000006615 aromatic heterocyclic group Chemical group 0.000 claims abstract description 18
229910052757 nitrogen Inorganic materials 0.000 claims abstract description 18
229910052736 halogen Inorganic materials 0.000 claims abstract description 17
150000002367 halogens Chemical class 0.000 claims abstract description 17
125000004432 carbon atom Chemical group C* 0.000 claims abstract description 12
125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 10
229910052760 oxygen Inorganic materials 0.000 claims abstract description 8
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 7
125000005842 heteroatom Chemical group 0.000 claims abstract description 7
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 7
125000004457 alkyl amino carbonyl group Chemical group 0.000 claims abstract description 6
229910052799 carbon Inorganic materials 0.000 claims abstract description 6
125000003107 substituted aryl group Chemical group 0.000 claims abstract description 6
125000000278 alkyl amino alkyl group Chemical group 0.000 claims abstract description 5
125000003277 amino group Chemical group 0.000 claims abstract description 5
125000001316 cycloalkyl alkyl group Chemical group 0.000 claims abstract description 5
125000005544 phthalimido group Chemical group 0.000 claims abstract description 5
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 4
125000004945 acylaminoalkyl group Chemical group 0.000 claims abstract description 3
125000004423 acyloxy group Chemical group 0.000 claims abstract description 3
125000003342 alkenyl group Chemical group 0.000 claims abstract description 3
125000004656 alkyl sulfonylamino group Chemical group 0.000 claims abstract description 3
125000005518 carboxamido group Chemical group 0.000 claims abstract description 3
125000001072 heteroaryl group Chemical group 0.000 claims abstract description 3
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 3
125000004183 alkoxy alkyl group Chemical group 0.000 claims abstract 2
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims abstract 2
238000000034 method Methods 0.000 claims description 28
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 13
238000011282 treatment Methods 0.000 claims description 13
125000003545 alkoxy group Chemical group 0.000 claims description 12
125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 11
230000008569 process Effects 0.000 claims description 10
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
150000002431 hydrogen Chemical class 0.000 claims description 6
239000008194 pharmaceutical composition Substances 0.000 claims description 6
125000005843 halogen group Chemical group 0.000 claims description 5
125000004043 oxo group Chemical group O=* 0.000 claims description 5
241000124008 Mammalia Species 0.000 claims description 4
125000004448 alkyl carbonyl group Chemical group 0.000 claims description 4
125000000753 cycloalkyl group Chemical group 0.000 claims description 4
125000002837 carbocyclic group Chemical group 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
230000001225 therapeutic effect Effects 0.000 claims description 3
125000003282 alkyl amino group Chemical group 0.000 claims description 2
231100000252 nontoxic Toxicity 0.000 claims description 2
230000003000 nontoxic effect Effects 0.000 claims description 2
125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
239000000126 substance Substances 0.000 claims description 2
SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical compound [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 claims 10
238000011321 prophylaxis Methods 0.000 claims 2
125000004093 cyano group Chemical group *C#N 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
150000003839 salts Chemical class 0.000 abstract description 20
125000001424 substituent group Chemical group 0.000 abstract description 9
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 7
125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 abstract 2
125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 2
125000006727 (C1-C6) alkenyl group Chemical group 0.000 abstract 1
125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 abstract 1
125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 abstract 1
239000012453 solvate Substances 0.000 abstract 1
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 174
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 143
239000000203 mixture Substances 0.000 description 96
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 78
235000019439 ethyl acetate Nutrition 0.000 description 71
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 57
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 54
239000008279 sol Substances 0.000 description 52
238000006243 chemical reaction Methods 0.000 description 47
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 45
239000003480 eluent Substances 0.000 description 43
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 42
239000011541 reaction mixture Substances 0.000 description 42
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 41
235000011114 ammonium hydroxide Nutrition 0.000 description 41
238000005481 NMR spectroscopy Methods 0.000 description 37
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 35
239000000741 silica gel Substances 0.000 description 33
229910002027 silica gel Inorganic materials 0.000 description 33
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 32
238000003818 flash chromatography Methods 0.000 description 30
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 29
239000011780 sodium chloride Substances 0.000 description 28
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 27
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 27
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
239000002904 solvent Substances 0.000 description 26
239000000243 solution Substances 0.000 description 25
239000012043 crude product Substances 0.000 description 19
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 19
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 18
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
239000000047 product Substances 0.000 description 18
239000007787 solid Substances 0.000 description 18
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 17
238000000921 elemental analysis Methods 0.000 description 16
CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 16
235000015165 citric acid Nutrition 0.000 description 15
229960004106 citric acid Drugs 0.000 description 15
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
239000000460 chlorine Substances 0.000 description 12
239000002253 acid Substances 0.000 description 11
238000001816 cooling Methods 0.000 description 11
208000035475 disorder Diseases 0.000 description 11
239000012044 organic layer Substances 0.000 description 11
239000003208 petroleum Substances 0.000 description 11
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 10
PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 10
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
238000010992 reflux Methods 0.000 description 10
239000003795 chemical substances by application Substances 0.000 description 9
230000000694 effects Effects 0.000 description 9
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 9
125000006413 ring segment Chemical group 0.000 description 9
UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 8
ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 8
239000003921 oil Substances 0.000 description 8
235000019198 oils Nutrition 0.000 description 8
229910000027 potassium carbonate Inorganic materials 0.000 description 8
235000015320 potassium carbonate Nutrition 0.000 description 8
239000007832 Na2SO4 Substances 0.000 description 7
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 7
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
125000004429 atom Chemical group 0.000 description 7
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 7
239000000499 gel Substances 0.000 description 7
239000000543 intermediate Substances 0.000 description 7
239000012279 sodium borohydride Substances 0.000 description 7
229910000033 sodium borohydride Inorganic materials 0.000 description 7
229910052938 sodium sulfate Inorganic materials 0.000 description 7
235000011152 sodium sulphate Nutrition 0.000 description 7
NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 6
238000005160 1H NMR spectroscopy Methods 0.000 description 6
ZSVACLAZDFXWQG-UHFFFAOYSA-N 3-methyl-2-phenylquinoline-4-carboxylic acid Chemical compound N1=C2C=CC=CC2=C(C(O)=O)C(C)=C1C1=CC=CC=C1 ZSVACLAZDFXWQG-UHFFFAOYSA-N 0.000 description 6
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
101001125071 Homo sapiens Neuromedin-K receptor Proteins 0.000 description 6
101000986989 Naja kaouthia Acidic phospholipase A2 CM-II Proteins 0.000 description 6
241000206607 Porphyra umbilicalis Species 0.000 description 6
230000003197 catalytic effect Effects 0.000 description 6
239000000706 filtrate Substances 0.000 description 6
IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 6
239000007788 liquid Substances 0.000 description 6
239000002808 molecular sieve Substances 0.000 description 6
XAPRFLSJBSXESP-UHFFFAOYSA-N oxycinchophen Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=C(O)C=1C1=CC=CC=C1 XAPRFLSJBSXESP-UHFFFAOYSA-N 0.000 description 6
URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 6
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 5
101800002813 Neurokinin-B Proteins 0.000 description 5
102100024304 Protachykinin-1 Human genes 0.000 description 5
150000002148 esters Chemical class 0.000 description 5
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 5
238000000746 purification Methods 0.000 description 5
235000017557 sodium bicarbonate Nutrition 0.000 description 5
229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
238000003756 stirring Methods 0.000 description 5
MSTDXOZUKAQDRL-UHFFFAOYSA-N 4-Chromanone Chemical compound C1=CC=C2C(=O)CCOC2=C1 MSTDXOZUKAQDRL-UHFFFAOYSA-N 0.000 description 4
OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 4
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
NHXYSAFTNPANFK-HDMCBQFHSA-N Neurokinin B Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCSC)NC(=O)[C@@H](N)CC(O)=O)C1=CC=CC=C1 NHXYSAFTNPANFK-HDMCBQFHSA-N 0.000 description 4
102000046798 Neurokinin B Human genes 0.000 description 4
108010040716 Neurokinin-3 Receptors Proteins 0.000 description 4
102000002003 Neurokinin-3 Receptors Human genes 0.000 description 4
102100029409 Neuromedin-K receptor Human genes 0.000 description 4
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
239000002585 base Substances 0.000 description 4
235000019400 benzoyl peroxide Nutrition 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
229910052794 bromium Inorganic materials 0.000 description 4
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 4
201000010099 disease Diseases 0.000 description 4
239000012458 free base Substances 0.000 description 4
125000001188 haloalkyl group Chemical group 0.000 description 4
239000010410 layer Substances 0.000 description 4
238000002844 melting Methods 0.000 description 4
230000008018 melting Effects 0.000 description 4
208000033808 peripheral neuropathy Diseases 0.000 description 4
239000000546 pharmaceutical excipient Substances 0.000 description 4
239000000843 powder Substances 0.000 description 4
150000003141 primary amines Chemical class 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
229920006395 saturated elastomer Polymers 0.000 description 4
239000000725 suspension Substances 0.000 description 4
238000001665 trituration Methods 0.000 description 4
AQFLVLHRZFLDDV-VIFPVBQESA-N (1s)-1-phenylpropan-1-amine Chemical compound CC[C@H](N)C1=CC=CC=C1 AQFLVLHRZFLDDV-VIFPVBQESA-N 0.000 description 3
ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 3
AQFLVLHRZFLDDV-UHFFFAOYSA-N 1-phenylpropan-1-amine Chemical compound CCC(N)C1=CC=CC=C1 AQFLVLHRZFLDDV-UHFFFAOYSA-N 0.000 description 3
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
241000700199 Cavia porcellus Species 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
108010010803 Gelatin Proteins 0.000 description 3
101000831616 Homo sapiens Protachykinin-1 Proteins 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
239000012359 Methanesulfonyl chloride Substances 0.000 description 3
SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
239000000654 additive Substances 0.000 description 3
230000001476 alcoholic effect Effects 0.000 description 3
239000005557 antagonist Substances 0.000 description 3
150000001721 carbon Chemical group 0.000 description 3
229910052801 chlorine Inorganic materials 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
238000004440 column chromatography Methods 0.000 description 3
PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 3
239000000945 filler Substances 0.000 description 3
229910052731 fluorine Inorganic materials 0.000 description 3
239000011737 fluorine Substances 0.000 description 3
238000009472 formulation Methods 0.000 description 3
239000007789 gas Substances 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 3
201000001119 neuropathy Diseases 0.000 description 3
230000007823 neuropathy Effects 0.000 description 3
239000002245 particle Substances 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
239000002002 slurry Substances 0.000 description 3
239000000600 sorbitol Substances 0.000 description 3
235000010356 sorbitol Nutrition 0.000 description 3
235000020357 syrup Nutrition 0.000 description 3
239000006188 syrup Substances 0.000 description 3
239000003826 tablet Substances 0.000 description 3
238000010626 work up procedure Methods 0.000 description 3
QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 2
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 2
CHZXTOCAICMPQR-UHFFFAOYSA-N 2-(2-bromoethyl)isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(CCBr)C(=O)C2=C1 CHZXTOCAICMPQR-UHFFFAOYSA-N 0.000 description 2
WZYBQONKMQQIDY-UHFFFAOYSA-N 3-amino-2-phenylquinoline-4-carboxylic acid Chemical compound N1=C2C=CC=CC2=C(C(O)=O)C(N)=C1C1=CC=CC=C1 WZYBQONKMQQIDY-UHFFFAOYSA-N 0.000 description 2
KFXNVYYLWUVEAO-UHFFFAOYSA-N 3-methyl-2-phenylquinoline-4-carbonyl chloride Chemical compound N1=C2C=CC=CC2=C(C(Cl)=O)C(C)=C1C1=CC=CC=C1 KFXNVYYLWUVEAO-UHFFFAOYSA-N 0.000 description 2
JMITZLAEEUNKAI-DEOSSOPVSA-N 4-oxo-4-[2-[2-phenyl-4-[[(1s)-1-phenylpropyl]carbamoyl]quinolin-3-yl]oxyethylamino]butanoic acid Chemical compound N([C@@H](CC)C=1C=CC=CC=1)C(=O)C(C1=CC=CC=C1N=1)=C(OCCNC(=O)CCC(O)=O)C=1C1=CC=CC=C1 JMITZLAEEUNKAI-DEOSSOPVSA-N 0.000 description 2
208000024827 Alzheimer disease Diseases 0.000 description 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
201000004624 Dermatitis Diseases 0.000 description 2
101000655188 Homo sapiens Tachykinin-3 Proteins 0.000 description 2
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
235000010643 Leucaena leucocephala Nutrition 0.000 description 2
240000007472 Leucaena leucocephala Species 0.000 description 2
208000019695 Migraine disease Diseases 0.000 description 2
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
HEAUFJZALFKPBA-YRVBCFNBSA-N Neurokinin A Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)O)C1=CC=CC=C1 HEAUFJZALFKPBA-YRVBCFNBSA-N 0.000 description 2
101800000399 Neurokinin A Proteins 0.000 description 2
102400000097 Neurokinin A Human genes 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
239000004820 Pressure-sensitive adhesive Substances 0.000 description 2
206010037211 Psychomotor hyperactivity Diseases 0.000 description 2
LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
101800003906 Substance P Proteins 0.000 description 2
102100033009 Tachykinin-3 Human genes 0.000 description 2
208000024780 Urticaria Diseases 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
125000002252 acyl group Chemical group 0.000 description 2
239000000556 agonist Substances 0.000 description 2
150000008064 anhydrides Chemical class 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
238000003556 assay Methods 0.000 description 2
HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
238000009835 boiling Methods 0.000 description 2
ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
239000011575 calcium Substances 0.000 description 2
239000002775 capsule Substances 0.000 description 2
150000001718 carbodiimides Chemical class 0.000 description 2
150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
238000004296 chiral HPLC Methods 0.000 description 2
239000013058 crude material Substances 0.000 description 2
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
239000007884 disintegrant Substances 0.000 description 2
239000003814 drug Substances 0.000 description 2
235000019441 ethanol Nutrition 0.000 description 2
238000001914 filtration Methods 0.000 description 2
238000001640 fractional crystallisation Methods 0.000 description 2
230000002496 gastric effect Effects 0.000 description 2
239000012442 inert solvent Substances 0.000 description 2
NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
239000008101 lactose Substances 0.000 description 2
239000003446 ligand Substances 0.000 description 2
239000007937 lozenge Substances 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
206010027599 migraine Diseases 0.000 description 2
238000002156 mixing Methods 0.000 description 2
PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 2
125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
230000001537 neural effect Effects 0.000 description 2
125000004433 nitrogen atom Chemical group N* 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
125000006239 protecting group Chemical group 0.000 description 2
238000000159 protein binding assay Methods 0.000 description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
208000017520 skin disease Diseases 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910000104 sodium hydride Inorganic materials 0.000 description 2
239000007921 spray Substances 0.000 description 2
239000008107 starch Substances 0.000 description 2
229940032147 starch Drugs 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Chemical compound C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 2
QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
BIIBYWQGRFWQKM-JVVROLKMSA-N (2S)-N-[4-(cyclopropylamino)-3,4-dioxo-1-[(3S)-2-oxopyrrolidin-3-yl]butan-2-yl]-2-[[(E)-3-(2,4-dichlorophenyl)prop-2-enoyl]amino]-4,4-dimethylpentanamide Chemical compound CC(C)(C)C[C@@H](C(NC(C[C@H](CCN1)C1=O)C(C(NC1CC1)=O)=O)=O)NC(/C=C/C(C=CC(Cl)=C1)=C1Cl)=O BIIBYWQGRFWQKM-JVVROLKMSA-N 0.000 description 1
HMHYXLVEFVGOPM-QKUYTOGTSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[2-[[(2s)-1-[[(2s)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]-methylamino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(3-carboxypropanoylamino)-4-oxobutan Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)N(C)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)CCC(O)=O)C1=CC=CC=C1 HMHYXLVEFVGOPM-QKUYTOGTSA-N 0.000 description 1
MHCVCKDNQYMGEX-UHFFFAOYSA-N 1,1'-biphenyl;phenoxybenzene Chemical group C1=CC=CC=C1C1=CC=CC=C1.C=1C=CC=CC=1OC1=CC=CC=C1 MHCVCKDNQYMGEX-UHFFFAOYSA-N 0.000 description 1
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
KGKAYWMGPDWLQZ-UHFFFAOYSA-N 1,2-bis(bromomethyl)benzene Chemical group BrCC1=CC=CC=C1CBr KGKAYWMGPDWLQZ-UHFFFAOYSA-N 0.000 description 1
CYSGHNMQYZDMIA-UHFFFAOYSA-N 1,3-Dimethyl-2-imidazolidinon Chemical compound CN1CCN(C)C1=O CYSGHNMQYZDMIA-UHFFFAOYSA-N 0.000 description 1
SHCFCJUJGBRSPO-UHFFFAOYSA-N 1-cyclohexylcyclohexan-1-amine Chemical compound C1CCCCC1C1(N)CCCCC1 SHCFCJUJGBRSPO-UHFFFAOYSA-N 0.000 description 1
LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
OEDMJTQRHMQBHD-UHFFFAOYSA-N 2-(2-bromopropyl)isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(CC(Br)C)C(=O)C2=C1 OEDMJTQRHMQBHD-UHFFFAOYSA-N 0.000 description 1
FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
BDOYKFSQFYNPKF-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;sodium Chemical compound [Na].[Na].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O BDOYKFSQFYNPKF-UHFFFAOYSA-N 0.000 description 1
YTRMTPPVNRALON-UHFFFAOYSA-N 2-phenyl-4-quinolinecarboxylic acid Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=CC=C1 YTRMTPPVNRALON-UHFFFAOYSA-N 0.000 description 1
HZBQVUNKJWEMQH-UHFFFAOYSA-N 3-(morpholin-4-ylmethyl)-2-phenylquinoline-4-carboxylic acid;hydrochloride Chemical compound Cl.C=1C=CC=CC=1C1=NC2=CC=CC=C2C(C(=O)O)=C1CN1CCOCC1 HZBQVUNKJWEMQH-UHFFFAOYSA-N 0.000 description 1
HBVZCPQDRDBTPN-UHFFFAOYSA-N 3-[[benzyl(methyl)amino]methyl]-2-phenylquinoline-4-carboxylic acid Chemical compound C=1C=CC=CC=1C=1N=C2C=CC=CC2=C(C(O)=O)C=1CN(C)CC1=CC=CC=C1 HBVZCPQDRDBTPN-UHFFFAOYSA-N 0.000 description 1
SIVXHFOPXAVCGW-UHFFFAOYSA-N 3-hydroxy-7-methyl-2-phenylquinoline-4-carboxylic acid Chemical compound N=1C2=CC(C)=CC=C2C(C(O)=O)=C(O)C=1C1=CC=CC=C1 SIVXHFOPXAVCGW-UHFFFAOYSA-N 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
AKHSBAVQPIRVAG-UHFFFAOYSA-N 4h-isochromene-1,3-dione Chemical compound C1=CC=C2C(=O)OC(=O)CC2=C1 AKHSBAVQPIRVAG-UHFFFAOYSA-N 0.000 description 1
HCXJFMDOHDNDCC-UHFFFAOYSA-N 5-$l^{1}-oxidanyl-3,4-dihydropyrrol-2-one Chemical group O=C1CCC(=O)[N]1 HCXJFMDOHDNDCC-UHFFFAOYSA-N 0.000 description 1
OOKPLZJDPAOXFM-NRFANRHFSA-N 9h-fluoren-9-ylmethyl n-[(1s)-2-chloro-2-oxo-1-phenylethyl]carbamate Chemical compound C1([C@H](NC(=O)OCC2C3=CC=CC=C3C3=CC=CC=C32)C(=O)Cl)=CC=CC=C1 OOKPLZJDPAOXFM-NRFANRHFSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
208000007848 Alcoholism Diseases 0.000 description 1
235000019489 Almond oil Nutrition 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
206010002027 Amyotrophy Diseases 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
239000004342 Benzoyl peroxide Substances 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
101710178035 Chorismate synthase 2 Proteins 0.000 description 1
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
235000001258 Cinchona calisaya Nutrition 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
208000027932 Collagen disease Diseases 0.000 description 1
208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 1
206010010741 Conjunctivitis Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
206010011224 Cough Diseases 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
101710152694 Cysteine synthase 2 Proteins 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
206010011953 Decreased activity Diseases 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
208000016192 Demyelinating disease Diseases 0.000 description 1
206010012335 Dependence Diseases 0.000 description 1
206010012442 Dermatitis contact Diseases 0.000 description 1
201000010374 Down Syndrome Diseases 0.000 description 1
239000004150 EU approved colour Substances 0.000 description 1
208000030814 Eating disease Diseases 0.000 description 1
101000737983 Enterobacter agglomerans Monofunctional chorismate mutase Proteins 0.000 description 1
241000277307 Esox Species 0.000 description 1
208000019454 Feeding and Eating disease Diseases 0.000 description 1
208000001640 Fibromyalgia Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
244000043261 Hevea brasiliensis Species 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000777134 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 43 Proteins 0.000 description 1
208000023105 Huntington disease Diseases 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
206010065390 Inflammatory pain Diseases 0.000 description 1
101150061776 Kcnip3 gene Proteins 0.000 description 1
238000005684 Liebig rearrangement reaction Methods 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
235000019759 Maize starch Nutrition 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
208000016285 Movement disease Diseases 0.000 description 1
101100162168 Mus musculus Adam1a gene Proteins 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
208000007920 Neurogenic Inflammation Diseases 0.000 description 1
102000003797 Neuropeptides Human genes 0.000 description 1
108090000189 Neuropeptides Proteins 0.000 description 1
240000007594 Oryza sativa Species 0.000 description 1
235000007164 Oryza sativa Nutrition 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
208000003251 Pruritus Diseases 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
208000028017 Psychotic disease Diseases 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
101100322557 Rattus norvegicus Adam1 gene Proteins 0.000 description 1
201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 description 1
208000013007 Rodent disease Diseases 0.000 description 1
206010039966 Senile dementia Diseases 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
239000004141 Sodium laurylsulphate Substances 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
102000003141 Tachykinin Human genes 0.000 description 1
108010072901 Tachykinin Receptors Proteins 0.000 description 1
102000007124 Tachykinin Receptors Human genes 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
206010044688 Trisomy 21 Diseases 0.000 description 1
102100031311 Ubiquitin carboxyl-terminal hydrolase 43 Human genes 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
206010046543 Urinary incontinence Diseases 0.000 description 1
JVVXZOOGOGPDRZ-SLFFLAALSA-N [(1R,4aS,10aR)-1,4a-dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthren-1-yl]methanamine Chemical compound NC[C@]1(C)CCC[C@]2(C)C3=CC=C(C(C)C)C=C3CC[C@H]21 JVVXZOOGOGPDRZ-SLFFLAALSA-N 0.000 description 1
INAPMGSXUVUWAF-GCVPSNMTSA-N [(2r,3s,5r,6r)-2,3,4,5,6-pentahydroxycyclohexyl] dihydrogen phosphate Chemical compound OC1[C@H](O)[C@@H](O)C(OP(O)(O)=O)[C@H](O)[C@@H]1O INAPMGSXUVUWAF-GCVPSNMTSA-N 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
125000004442 acylamino group Chemical group 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000036428 airway hyperreactivity Effects 0.000 description 1
201000007930 alcohol dependence Diseases 0.000 description 1
239000003513 alkali Substances 0.000 description 1
125000005078 alkoxycarbonylalkyl group Chemical group 0.000 description 1
150000003973 alkyl amines Chemical class 0.000 description 1
125000005196 alkyl carbonyloxy group Chemical group 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
230000007815 allergy Effects 0.000 description 1
239000008168 almond oil Substances 0.000 description 1
239000004411 aluminium Substances 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
HOPRXXXSABQWAV-UHFFFAOYSA-N anhydrous collidine Natural products CC1=CC=NC(C)=C1C HOPRXXXSABQWAV-UHFFFAOYSA-N 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
239000000010 aprotic solvent Substances 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
239000008135 aqueous vehicle Substances 0.000 description 1
150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
125000005129 aryl carbonyl group Chemical group 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
150000001540 azides Chemical class 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
229960003328 benzoyl peroxide Drugs 0.000 description 1
AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000012267 brine Substances 0.000 description 1
230000031709 bromination Effects 0.000 description 1
238000005893 bromination reaction Methods 0.000 description 1
125000005997 bromomethyl group Chemical group 0.000 description 1
239000000872 buffer Substances 0.000 description 1
244000309464 bull Species 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
150000001244 carboxylic acid anhydrides Chemical class 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
WBLIXGSTEMXDSM-UHFFFAOYSA-N chloromethane Chemical compound Cl[CH2] WBLIXGSTEMXDSM-UHFFFAOYSA-N 0.000 description 1
LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
UTBIMNXEDGNJFE-UHFFFAOYSA-N collidine Natural products CC1=CC=C(C)C(C)=N1 UTBIMNXEDGNJFE-UHFFFAOYSA-N 0.000 description 1
238000004040 coloring Methods 0.000 description 1
235000008504 concentrate Nutrition 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
208000010247 contact dermatitis Diseases 0.000 description 1
230000008602 contraction Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
238000010511 deprotection reaction Methods 0.000 description 1
239000007933 dermal patch Substances 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
235000014632 disordered eating Nutrition 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
208000024732 dysthymic disease Diseases 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
206010015037 epilepsy Diseases 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
208000006275 fascioliasis Diseases 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013312 flour Nutrition 0.000 description 1
230000037406 food intake Effects 0.000 description 1
235000012631 food intake Nutrition 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
230000006870 function Effects 0.000 description 1
238000002825 functional assay Methods 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000008103 glucose Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
230000002140 halogenating effect Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
229910000042 hydrogen bromide Inorganic materials 0.000 description 1
125000002768 hydroxyalkyl group Chemical group 0.000 description 1
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
210000003405 ileum Anatomy 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
239000002198 insoluble material Substances 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000001282 iso-butane Substances 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
238000003760 magnetic stirring Methods 0.000 description 1
229960002510 mandelic acid Drugs 0.000 description 1
239000000463 material Substances 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
BRMYZIKAHFEUFJ-UHFFFAOYSA-L mercury diacetate Chemical compound CC(=O)O[Hg]OC(C)=O BRMYZIKAHFEUFJ-UHFFFAOYSA-L 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
125000001064 morpholinomethyl group Chemical group [H]C([H])(*)N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
HHQJWDKIRXRTLS-UHFFFAOYSA-N n'-bromobutanediamide Chemical compound NC(=O)CCC(=O)NBr HHQJWDKIRXRTLS-UHFFFAOYSA-N 0.000 description 1
RIWRFSMVIUAEBX-UHFFFAOYSA-N n-methyl-1-phenylmethanamine Chemical compound CNCC1=CC=CC=C1 RIWRFSMVIUAEBX-UHFFFAOYSA-N 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
229920003052 natural elastomer Polymers 0.000 description 1
229920001194 natural rubber Polymers 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
239000002746 neurokinin 2 receptor antagonist Substances 0.000 description 1
230000002981 neuropathic effect Effects 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
239000002687 nonaqueous vehicle Substances 0.000 description 1
229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
230000037361 pathway Effects 0.000 description 1
YZTJYBJCZXZGCT-UHFFFAOYSA-N phenylpiperazine Chemical group C1CNCCN1C1=CC=CC=C1 YZTJYBJCZXZGCT-UHFFFAOYSA-N 0.000 description 1
NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 1
125000004193 piperazinyl group Chemical group 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
FYRHIOVKTDQVFC-UHFFFAOYSA-M potassium phthalimide Chemical compound [K+].C1=CC=C2C(=O)[N-]C(=O)C2=C1 FYRHIOVKTDQVFC-UHFFFAOYSA-M 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
229960004919 procaine Drugs 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
239000003380 propellant Substances 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
239000003586 protic polar solvent Substances 0.000 description 1
239000012264 purified product Substances 0.000 description 1
229960000948 quinine Drugs 0.000 description 1
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
230000006340 racemization Effects 0.000 description 1
239000000018 receptor agonist Substances 0.000 description 1
229940044601 receptor agonist Drugs 0.000 description 1
238000006268 reductive amination reaction Methods 0.000 description 1
208000023504 respiratory system disease Diseases 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
206010039083 rhinitis Diseases 0.000 description 1
235000009566 rice Nutrition 0.000 description 1
238000006798 ring closing metathesis reaction Methods 0.000 description 1
102220079670 rs759826252 Human genes 0.000 description 1
201000000980 schizophrenia Diseases 0.000 description 1
108010016070 senktide Proteins 0.000 description 1
230000020341 sensory perception of pain Effects 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
229940080313 sodium starch Drugs 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
230000000392 somatic effect Effects 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000001593 sorbitan monooleate Substances 0.000 description 1
235000011069 sorbitan monooleate Nutrition 0.000 description 1
229940035049 sorbitan monooleate Drugs 0.000 description 1
210000005070 sphincter Anatomy 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
239000000758 substrate Substances 0.000 description 1
229940014800 succinic anhydride Drugs 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
238000000967 suction filtration Methods 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
239000002278 tabletting lubricant Substances 0.000 description 1
108060008037 tachykinin Proteins 0.000 description 1
239000002466 tachykinin receptor agonist Substances 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
230000007306 turnover Effects 0.000 description 1
230000002455 vasospastic effect Effects 0.000 description 1
239000003981 vehicle Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
- C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Neurosurgery (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

OA9800062A 1995-11-24 1998-05-22 Quinoline-4-carboxamide derivatives their preparation and their use as neurokin 3 (nk-3)-and neurokin 2 (nk-2)receptor antagonists OA11011A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
ITMI952462 IT1276171B1 (it)	1995-11-24	1995-11-24	Derivati chinolinici
IT96MI001688 IT1307330B1 (it)	1996-08-02	1996-08-02	Derivati chinolinici

Publications (1)

Publication Number	Publication Date
OA11011A true OA11011A (en)	2003-03-06

Family

ID=26331327

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA9800062A OA11011A (en)	1995-11-24	1998-05-22	Quinoline-4-carboxamide derivatives their preparation and their use as neurokin 3 (nk-3)-and neurokin 2 (nk-2)receptor antagonists

Country Status (26)

Country	Link
US (1)	US20020068827A1 (fr)
EP (1)	EP1019377A1 (fr)
JP (1)	JP2000513325A (fr)
KR (1)	KR19990071598A (fr)
CN (1)	CN1207729A (fr)
AP (1)	AP9801238A0 (fr)
AR (1)	AR004735A1 (fr)
AU (1)	AU1031897A (fr)
BG (1)	BG102557A (fr)
BR (1)	BR9611757A (fr)
CA (1)	CA2238328A1 (fr)
CZ (1)	CZ158098A3 (fr)
DZ (1)	DZ2128A1 (fr)
EA (1)	EA001771B1 (fr)
HU (1)	HUP9901016A3 (fr)
IL (1)	IL124418A0 (fr)
MA (1)	MA24011A1 (fr)
MX (1)	MX9804108A (fr)
NO (1)	NO311213B1 (fr)
OA (1)	OA11011A (fr)
PL (1)	PL326928A1 (fr)
SK (1)	SK66898A3 (fr)
TR (1)	TR199800883T2 (fr)
TW (1)	TW409123B (fr)
UY (2)	UY24375A1 (fr)
WO (1)	WO1997019926A1 (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6100267A (en) *	1997-03-14	2000-08-08	Smithkline Beecham Corporation	Quinoline- and naphthalenecarboxamides, pharmaceutical compositions and methods of inhibiting calpain
CN1264378A (zh) *	1997-05-23	2000-08-23	史密丝克莱恩比彻姆股份公司	作为nk－2和nk－3受体拮抗剂的喹啉－4－甲酰胺衍生物
US6339089B2 (en)	1997-08-13	2002-01-15	Fujirebio Inc.	Pyrimidine nucleus-containing compound and a medicament containing the same for a blood oxygen partial pressure amelioration, and a method for preparing the same
US6262070B1 (en)	1998-11-04	2001-07-17	Darwin Discovery Ltd.	Heterocyclic compounds and their therapeutic use
GB9825554D0 (en) *	1998-11-20	1999-01-13	Smithkline Beecham Spa	Novel Compounds
US6780875B2 (en) *	1998-11-20	2004-08-24	Smithkline Beecham S.P.A.	Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists
JP2002530377A (ja) *	1998-11-20	2002-09-17	スミスクライン・ビーチャム・ソシエタ・ペル・アチオニ	Ｎｋ−３およびｎｋ−２受容体アンタゴニストとしてのキノリン−４−カルボキシアミド誘導体
EP1035115B1 (fr) *	1999-02-24	2004-09-29	F. Hoffmann-La Roche Ag	Dérivés de 4-phenylpyridine et leur utilisation comme antagonistes du recepteur NK-1
US7037922B1 (en)	2000-03-10	2006-05-02	Neurogen Corporation	Aryl fused 2,4-disubstituted pyridines: NK3 receptor ligands
DE60003899T2 (de) *	1999-03-11	2004-05-27	Neurogen Corp., Branford	Aryl-annellierte disubstituierte pyridine : nk3 rezeptor-liganden
ATE247652T1 (de)	1999-03-29	2003-09-15	Neurogen Corp	4-substituierte chinolinderivate als nk-3 und/oder gaba(a) rezeptor liganden
WO2000064877A1 (fr) *	1999-04-26	2000-11-02	Neurogen Corporation	2-aminoquinolinecarboxamides: ligands de recepteurs de la neurokinine
TWI259180B (en) *	2000-08-08	2006-08-01	Hoffmann La Roche	4-Phenyl-pyridine derivatives
WO2002013825A1 (fr) *	2000-08-11	2002-02-21	Smithkline Beecham P.L.C.	Nouvelle utilisation pharmaceutique de dérivés quinnoliniques
EP1334089A1 (fr) *	2000-11-13	2003-08-13	GlaxoSmithKline S.p.A.	Derives de la quinoline en tant qu'antagonistes de nk-3 et nk-2
GB0028964D0 (en) *	2000-11-28	2001-01-10	Smithkline Beecham Spa	Novel compounds
US6540733B2 (en)	2000-12-29	2003-04-01	Corazon Technologies, Inc.	Proton generating catheters and methods for their use in enhancing fluid flow through a vascular site occupied by a calcified vascular occlusion
EP1385839B1 (fr) *	2001-04-11	2006-02-22	GlaxoSmithKline S.p.A.	Derives de 3-substitue quinoline-4-carboxamide utilises comme antagonistes du recepteur nk3 et du recepteur nk2
GB0109122D0 (en) *	2001-04-11	2001-05-30	Smithkline Beecham Spa	Novel compounds
MY134211A (en) *	2001-05-18	2007-11-30	Smithkline Beecham Corp	Novel use
EP1541149A1 (fr) *	2002-06-26	2005-06-15	Kyowa Hakko Kogyo Co., Ltd.	Inhibiteur de phosphodiesterase
GB0312609D0 (en)	2003-06-02	2003-07-09	Astrazeneca Ab	Novel compounds
EP1635834A4 (fr) *	2003-06-25	2009-12-02	Smithkline Beecham Corp	Nouveaux composes
US7288658B2 (en)	2003-07-15	2007-10-30	Hoffmann-La Roche Inc.	Process for preparation of pyridine derivatives
SE0302139D0 (sv) *	2003-07-28	2003-07-28	Astrazeneca Ab	Novel compounds
GB0318727D0 (en) *	2003-08-08	2003-09-10	Smithkline Beecham Corp	Novel compounds
GB0425077D0 (en) *	2004-11-12	2004-12-15	Smithkline Beecham Corp	Novel compounds
CA2611060A1 (fr) *	2005-06-03	2006-12-07	R. Thomas Simpson	Derives de quinoline utilises comme antagonistes de nk3
WO2006137789A1 (fr) *	2005-06-23	2006-12-28	Astrazeneca Ab	Esters de quinoline-3-sulfonate en tant que régulateurs de récepteurs nk3
GB0515580D0 (en)	2005-07-29	2005-09-07	Merck Sharp & Dohme	Therapeutic compounds
CN101282961A (zh) *	2005-08-11	2008-10-08	阿斯利康(瑞典)有限公司	作为nk3受体调节剂的烷基吡啶基喹啉
US20080280949A1 (en) *	2005-08-11	2008-11-13	Astrazeneca Ab	Oxopyridyl Quinoline Amides as Nk3 Receptor Modulators
WO2007018465A1 (fr) *	2005-08-11	2007-02-15	Astrazeneca Ab	Amide alkyl pyridiyl quinolines en tant que modulateurs du récepteur des nk3
AR058051A1 (es) *	2005-09-21	2008-01-23	Astrazeneca Ab	Quinolinas de alquilnitrilo.proceso de obtencion y composiciones farmaceuticas.
AR057130A1 (es)	2005-09-21	2007-11-14	Astrazeneca Ab	Quinolinas de alquilsulfoxido y una composicion farmaceutica
TW201018662A (en)	2005-12-12	2010-05-16	Astrazeneca Ab	Alkylsulphonamide quinolines
RU2460727C2 (ru)	2007-03-22	2012-09-10	Астразенека Аб	Хинолиновые производные для лечения воспалительных заболеваний
PE20091036A1 (es)	2007-11-30	2009-08-15	Astrazeneca Ab	Derivado de quinolina como antagonista del receptor p2x7
CN102924375B (zh) *	2012-06-21	2015-02-18	江苏恩华药业股份有限公司	Talnetant中间体及其制备方法和应用
BR112015026519A2 (pt)	2013-04-19	2017-07-25	Astrazeneca Ab	composto antagonista do receptor nk3 (nk3ra) para uso em um método destinado ao tratamento de síndrome do ovário policístico (sop)
US10189788B2 (en)	2014-09-09	2019-01-29	Bayer Pharma Aktiengesellschaft	Substituted N,2-diarylquinoline-4-carboxamides and the use thereof as anti-inflammatory agents
EP3271334A1 (fr)	2015-03-18	2018-01-24	Bayer Pharma Aktiengesellschaft	N-bicyclo-2-arylchinolino-4-carboxamides substitués et leur utilisation
WO2017072629A1 (fr)	2015-10-29	2017-05-04	Cadila Healthcare Limited	Combinaison pharmaceutique d'antagoniste du récepteur nk3 et de biguanides
WO2017153234A1 (fr)	2016-03-09	2017-09-14	Bayer Pharma Aktiengesellschaft	N-cyclo-2-arylchinolin-4-carboxamides substitués et leur utilisation
WO2017153235A1 (fr)	2016-03-09	2017-09-14	Bayer Pharma Aktiengesellschaft	N-cyclo-3-aryl-1-naphthamides substitués et leur utilisation
WO2017153231A1 (fr)	2016-03-09	2017-09-14	Bayer Pharma Aktiengesellschaft	N-cyclo-2-arylisochinolinon-4-carboxamides substitués et leur utilisation
TWI770157B (zh) *	2017-04-10	2022-07-11	德商拜耳廠股份有限公司	經取代之n-芳基乙基-2-胺基喹啉-4-甲醯胺及其用途
PE20191616A1 (es)	2017-04-10	2019-11-05	Bayer Ag	N-ariletil-2-arilquinolina-4-carboxamidas sustituidas y su uso

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2538388B1 (fr) *	1982-12-24	1985-06-21	Pharmuka Lab	Nouveaux derives de naphtalene- ou azanaphtalenecarboxamide, leurs procedes de preparation et leur utilisation comme medicaments
DK623586A (da) *	1985-12-27	1987-06-28	Eisai Co Ltd	Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne
DE69315920T2 (de) *	1992-09-04	1998-06-10	Takeda Chemical Industries Ltd	Kondensierte heterozyklische Verbindungen, deren Herstellung und Verwendung
DE69531458T2 (de) *	1994-05-27	2004-08-05	Glaxosmithkline S.P.A.	Chinolinderivate als tachykinin nk3 rezeptor antagonisten
IT1270615B (it) *	1994-07-14	1997-05-07	Smithkline Beecham Farma	Uso di derivati di chinolina

1996
- 1996-11-21 AR ARP960105282A patent/AR004735A1/es unknown
- 1996-11-22 MA MA24399A patent/MA24011A1/fr unknown
- 1996-11-22 KR KR1019980703874A patent/KR19990071598A/ko not_active Withdrawn
- 1996-11-22 AP APAP/P/1998/001238A patent/AP9801238A0/en unknown
- 1996-11-22 WO PCT/EP1996/005207 patent/WO1997019926A1/fr not_active Ceased
- 1996-11-22 CN CN96199747A patent/CN1207729A/zh active Pending
- 1996-11-22 AU AU10318/97A patent/AU1031897A/en not_active Abandoned
- 1996-11-22 SK SK668-98A patent/SK66898A3/sk unknown
- 1996-11-22 EP EP96941025A patent/EP1019377A1/fr not_active Withdrawn
- 1996-11-22 PL PL96326928A patent/PL326928A1/xx unknown
- 1996-11-22 JP JP09520158A patent/JP2000513325A/ja active Pending
- 1996-11-22 UY UY24375A patent/UY24375A1/es not_active IP Right Cessation
- 1996-11-22 CZ CZ981580A patent/CZ158098A3/cs unknown
- 1996-11-22 IL IL12441896A patent/IL124418A0/xx unknown
- 1996-11-22 TR TR1998/00883T patent/TR199800883T2/xx unknown
- 1996-11-22 HU HU9901016A patent/HUP9901016A3/hu unknown
- 1996-11-22 EA EA199800538A patent/EA001771B1/ru not_active IP Right Cessation
- 1996-11-22 CA CA002238328A patent/CA2238328A1/fr not_active Abandoned
- 1996-11-22 BR BR9611757A patent/BR9611757A/pt unknown
- 1996-11-23 TW TW085114501A patent/TW409123B/zh not_active IP Right Cessation
- 1996-11-23 DZ DZ960173A patent/DZ2128A1/fr active
1997
- 1997-05-16 UY UY24555A patent/UY24555A1/es not_active Application Discontinuation
1998
- 1998-05-22 MX MX9804108A patent/MX9804108A/es unknown
- 1998-05-22 OA OA9800062A patent/OA11011A/en unknown
- 1998-05-22 NO NO19982333A patent/NO311213B1/no not_active IP Right Cessation
- 1998-06-18 BG BG102557A patent/BG102557A/bg unknown
2001
- 2001-11-26 US US09/994,402 patent/US20020068827A1/en not_active Abandoned

Also Published As

Publication number	Publication date
BR9611757A (pt)	1999-04-06
MA24011A1 (fr)	1997-07-01
WO1997019926A1 (fr)	1997-06-05
HUP9901016A2 (hu)	2000-03-28
NO311213B1 (no)	2001-10-29
IL124418A0 (en)	1998-12-06
JP2000513325A (ja)	2000-10-10
US20020068827A1 (en)	2002-06-06
CA2238328A1 (fr)	1997-06-05
EP1019377A1 (fr)	2000-07-19
AR004735A1 (es)	1999-03-10
UY24375A1 (es)	1997-05-22
PL326928A1 (en)	1998-11-09
CN1207729A (zh)	1999-02-10
AU1031897A (en)	1997-06-19
AP9801238A0 (en)	1998-06-30
BG102557A (bg)	1999-03-31
HUP9901016A3 (en)	2002-01-28
NO982333D0 (no)	1998-05-22
TW409123B (en)	2000-10-21
MX9804108A (es)	1998-09-30
DZ2128A1 (fr)	2002-10-26
UY24555A1 (es)	2001-04-30
EA001771B1 (ru)	2001-08-27
CZ158098A3 (cs)	1998-10-14
TR199800883T2 (xx)	2000-12-21
EA199800538A1 (ru)	1998-12-24
KR19990071598A (ko)	1999-09-27
NO982333L (no)	1998-07-22
SK66898A3 (en)	1998-12-02

Publication	Publication Date	Title
US6277862B1 (en)	2001-08-21	Quinoline derivatives
US20020068827A1 (en)	2002-06-06	Quinoline-4-carboxamide derivatives, their preparation and their use as neurokinin 3 ( NK-3 ) - and neurokinin 2 ( NK-3 ) receptor antagonists
WO1997021680A9 (fr)	1997-09-12	Derives de quinoline
EP1377555B1 (fr)	2007-01-24	Un derive de dioxino[2,3-g]quinoline-9-acide carboxylique en tant qu'antagoniste du recepteur nk3
NZ511777A (en)	2003-12-19	Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists
EP0983262B1 (fr)	2003-07-09	Derives de quinoline-4-carboxamide comme antagonistes des recepteurs nk-2 et nk-3
EP1385839B1 (fr)	2006-02-22	Derives de 3-substitue quinoline-4-carboxamide utilises comme antagonistes du recepteur nk3 et du recepteur nk2
EP1131294B1 (fr)	2006-12-20	Derives de quinoline utilises comme ligands des recepteurs nk-2 et nk-3
US20040077658A1 (en)	2004-04-22	Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
US6780875B2 (en)	2004-08-24	Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists
US20070197546A1 (en)	2007-08-23	Quinoline-4-carboxamide as nk-2 and nk-3 receptor antagonists
AU4263200A (en)	2000-11-30	Quinoline-4-carboxamide derivatives, their preparation and their use as neurokinin 3 (NK-3)- and neurokinin 2 (NK-2) receptor antagonists
Luca et al.	0	PCT WORLD) INTELLECTUAL PROPERTY ORGANIZATION
AU1031797A (en)	1997-07-03	Quinoline derivatives
KR20010012823A (ko)	2001-02-26	Ｎｋ-2 및 ｎｋ-3 수용체 길항제로서의퀴놀린-4-카르복스아미드 유도체
MXPA99010841A (en)	2000-07-01	Quinoline-4-carboxamide derivatives as nk-2 and nk-3 receptor antagonists
CZ416199A3 (cs)	2000-08-16	Chinolin-4-karboxamidové deriváty jako antagonisté receptoru pro NK-2 a NK-3